Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02883491 · ClinicalTrials.gov registry record
Pulmonary Embolism Short-term Clinical Outcomes Registry
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 815
- Enrollment target
NCT02883491: Completed study, sponsored by Wake Forest University Health Sciences.
NCT02883491 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 815 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02883491 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 815 participants
- Enrollment target
Study Summary
The overall goal of this clinical research study is to prospectively assess primary outcomes related to pulmonary embolism (PE) that occur immediately (within 5 days) and within 30 days. The secondary goal is to compare validated prediction models and a modified European Society of Cardiology (ESC) approach that is primarily right ventricle dysfunction (RVD) driven with clinical risk assessment being secondary, and with primary outcomes of clinical deterioration within 5 days.
Primary Outcome
Presence of any one clinical deterioration variable: death, circulatory or respiratory dysfunction, reperfusion interventions.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 815 participants |
| Start Date | 2016-08 |
| Est. Completion | 2019-02-20 |
What the finished NCT02883491 record still lists
NCT02883491 is an observational study that tracks outcomes without assigning an intervention. The registered 815 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02883491 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02883491 about?
NCT02883491 is a clinical study titled "Pulmonary Embolism Short-term Clinical Outcomes Registry". The overall goal of this clinical research study is to prospectively assess primary outcomes related to pulmonary embolism (PE) that occur immediately (within 5 days) and within 30 days. The secondary goal is to compare validated prediction models and a modified European Society of Cardiology (ESC) ...
What is the current status of trial NCT02883491?
This trial is currently completed. The enrollment target is 815 participants. The study started on 2016-08. Estimated completion is 2019-02-20.
Who is sponsoring clinical trial NCT02883491?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07218029 · 815 participants · Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
- NCT04846959 · 818 participants
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
- NCT04613440 · 820 participants · NA
FaCT Trial (Facilitated Cascade Testing Trial)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia